Endong Chen, Chen Chen, Yingying Chen, Jie You, Nan Chen, Shenlin Xu, Qingxuan Wang, Yefeng Cai, Xiaoqu Hu, Quan Li
{"title":"研究早期乳腺癌中的 HER2 低值：预后意义和与年龄相关的预后分层","authors":"Endong Chen, Chen Chen, Yingying Chen, Jie You, Nan Chen, Shenlin Xu, Qingxuan Wang, Yefeng Cai, Xiaoqu Hu, Quan Li","doi":"10.1002/cam4.70637","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Recent studies about human epidermal growth factor receptor 2 (HER2)-low values have garnered great interest among oncologists. We aimed to investigate whether HER2-low impacts the prognosis of early-stage breast cancer overall and in specific subgroups, explore differences in clinicopathologic markers, and examine the role of age in HER2-low prognostic stratification.</p>\n </section>\n \n <section>\n \n <h3> Materials & Methods</h3>\n \n <p>We conducted a retrospective analysis of 6920 HER2-negative breast cancer patients from the First Affiliated Hospital of Wenzhou Medical University (2010–2022). The study focused on the impact of HER2-low status (immunohistochemistry +1 or +2, in situ hybridization not amplified) on overall survival (OS), considering the age at diagnosis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Generally, HER2-low status correlated with less aggressive cancer indicators. No significant prognostic differences were observed between HER2-low and HER2-0 in the entire cohort, HR-positive, and HR-negative groups. However, in TNBC patients aged ≥ 65, HER2-low correlated with significantly better OS (HR = 0.45, 95% CI 0.24–0.83, <i>p</i> = 0.011), a finding consistent after multivariable adjustment (HR = 0.34, 95% CI 0.14–0.80, <i>p</i> = 0.014). In other subgroups, prognosis did not significantly correlate with HER2 status. The combination of HER2-low status and age plays a key role in prognostic stratification in TNBC. Patients aged ≥ 65 with HER2-0 had considerably poorer prognoses compared to other subgroups.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This extensive retrospective study demonstrates that HER2-low status cannot serve as an independent prognostic factor in the entire cohort, nor in the HR-positive and HR-negative groups individually. However, the combined factors of HER2-low status and age may indicate a potential contribution to the prognostic stratification of TNBC.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 4","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70637","citationCount":"0","resultStr":"{\"title\":\"Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification\",\"authors\":\"Endong Chen, Chen Chen, Yingying Chen, Jie You, Nan Chen, Shenlin Xu, Qingxuan Wang, Yefeng Cai, Xiaoqu Hu, Quan Li\",\"doi\":\"10.1002/cam4.70637\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Recent studies about human epidermal growth factor receptor 2 (HER2)-low values have garnered great interest among oncologists. We aimed to investigate whether HER2-low impacts the prognosis of early-stage breast cancer overall and in specific subgroups, explore differences in clinicopathologic markers, and examine the role of age in HER2-low prognostic stratification.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials & Methods</h3>\\n \\n <p>We conducted a retrospective analysis of 6920 HER2-negative breast cancer patients from the First Affiliated Hospital of Wenzhou Medical University (2010–2022). The study focused on the impact of HER2-low status (immunohistochemistry +1 or +2, in situ hybridization not amplified) on overall survival (OS), considering the age at diagnosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Generally, HER2-low status correlated with less aggressive cancer indicators. No significant prognostic differences were observed between HER2-low and HER2-0 in the entire cohort, HR-positive, and HR-negative groups. However, in TNBC patients aged ≥ 65, HER2-low correlated with significantly better OS (HR = 0.45, 95% CI 0.24–0.83, <i>p</i> = 0.011), a finding consistent after multivariable adjustment (HR = 0.34, 95% CI 0.14–0.80, <i>p</i> = 0.014). In other subgroups, prognosis did not significantly correlate with HER2 status. The combination of HER2-low status and age plays a key role in prognostic stratification in TNBC. Patients aged ≥ 65 with HER2-0 had considerably poorer prognoses compared to other subgroups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This extensive retrospective study demonstrates that HER2-low status cannot serve as an independent prognostic factor in the entire cohort, nor in the HR-positive and HR-negative groups individually. However, the combined factors of HER2-low status and age may indicate a potential contribution to the prognostic stratification of TNBC.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 4\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-02-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70637\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70637\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70637","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
近年来，关于人表皮生长因子受体2 （HER2）低值的研究引起了肿瘤学家的极大兴趣。我们的目的是研究her2低水平是否会影响早期乳腺癌整体和特定亚组的预后，探讨临床病理标志物的差异，并检查年龄在her2低水平预后分层中的作用。材料,方法对2010-2022年温州医科大学第一附属医院her2阴性乳腺癌患者6920例进行回顾性分析。该研究的重点是考虑到诊断时的年龄，her2低状态（免疫组织化学+1或+2，原位杂交未扩增）对总生存率（OS）的影响。结果一般来说，her2低状态与侵袭性较低的癌症指标相关。在整个队列、hr阳性组和hr阴性组中，her2 -低和HER2-0的预后无显著差异。然而，在年龄≥65岁的TNBC患者中，her2 -低与更好的OS显著相关（HR = 0.45, 95% CI 0.24-0.83, p = 0.011），多变量调整后的结果一致（HR = 0.34, 95% CI 0.14-0.80, p = 0.014）。在其他亚组中，预后与HER2状态无显著相关性。her2低状态和年龄的结合在TNBC的预后分层中起关键作用。与其他亚组相比，年龄≥65岁的HER2-0患者预后明显较差。结论这项广泛的回顾性研究表明，her2低状态不能作为整个队列的独立预后因素，也不能单独作为hr阳性和hr阴性组的预后因素。然而，her2低状态和年龄的综合因素可能对TNBC的预后分层有潜在的贡献。
Investigating HER2-Low in Early Breast Cancer: Prognostic Implications and Age-Related Prognostic Stratification
Background
Recent studies about human epidermal growth factor receptor 2 (HER2)-low values have garnered great interest among oncologists. We aimed to investigate whether HER2-low impacts the prognosis of early-stage breast cancer overall and in specific subgroups, explore differences in clinicopathologic markers, and examine the role of age in HER2-low prognostic stratification.
Materials & Methods
We conducted a retrospective analysis of 6920 HER2-negative breast cancer patients from the First Affiliated Hospital of Wenzhou Medical University (2010–2022). The study focused on the impact of HER2-low status (immunohistochemistry +1 or +2, in situ hybridization not amplified) on overall survival (OS), considering the age at diagnosis.
Results
Generally, HER2-low status correlated with less aggressive cancer indicators. No significant prognostic differences were observed between HER2-low and HER2-0 in the entire cohort, HR-positive, and HR-negative groups. However, in TNBC patients aged ≥ 65, HER2-low correlated with significantly better OS (HR = 0.45, 95% CI 0.24–0.83, p = 0.011), a finding consistent after multivariable adjustment (HR = 0.34, 95% CI 0.14–0.80, p = 0.014). In other subgroups, prognosis did not significantly correlate with HER2 status. The combination of HER2-low status and age plays a key role in prognostic stratification in TNBC. Patients aged ≥ 65 with HER2-0 had considerably poorer prognoses compared to other subgroups.
Conclusion
This extensive retrospective study demonstrates that HER2-low status cannot serve as an independent prognostic factor in the entire cohort, nor in the HR-positive and HR-negative groups individually. However, the combined factors of HER2-low status and age may indicate a potential contribution to the prognostic stratification of TNBC.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
